Cargando…

CD80 and CTLA-4 as diagnostic and prognostic markers in adult-onset minimal change disease: a retrospective study

BACKGROUND: Minimal change disease (MCD) is a form of idiopathic nephrotic syndrome. Compared to children, adult-onset MCD patients are reported to have delayed responses to glucocorticoid treatment. Several studies of children have suggested detecting urinary CD80 levels to diagnose MCD. There are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Bing, Han, Hui, Zhen, Junhui, Yang, Xiaowei, Shang, Jin, Xu, Liang, Wang, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078067/ https://www.ncbi.nlm.nih.gov/pubmed/30083478 http://dx.doi.org/10.7717/peerj.5400

Ejemplares similares

sCD28, sCD80, sCTLA-4, and sBTLA Are Promising Markers in Diagnostic and Therapeutic Approaches for Aseptic Loosening and Periprosthetic Joint Infection
por: Jubel, Jil M., et al.
Publicado: (2021)

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
por: Ville, Simon, et al.
Publicado: (2015)

Molecular and Functional Analyses of the Primordial Costimulatory Molecule CD80/86 and Its Receptors CD28 and CD152 (CTLA-4) in a Teleost Fish
por: Lu, Tao-Zhen, et al.
Publicado: (2022)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
por: Lin, Shouheng, et al.
Publicado: (2021)

Usefulness of the cytokines expression of Th1/Th2/Th17 and urinary CD80 excretion in adult-onset minimal change disease
por: Chen, Ping, et al.
Publicado: (2020)

Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
por: Krausz, Máté, et al.
Publicado: (2022)

Corrigendum: Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
por: Krausz, Máté, et al.
Publicado: (2023)

Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer
por: Świderska, Janina, et al.
Publicado: (2022)

Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset
por: Steiner, Sophie, et al.
Publicado: (2020)

Interferon Gamma Induces the Increase of Cell-Surface Markers (CD80/86, CD83 and MHC-II) in Splenocytes From Atlantic Salmon
por: Morales-Lange, Byron, et al.
Publicado: (2021)

Modulation of Regulatory T Cells Activity by Distinct CD80 and CD86 Interactions With CD28/CTLA-4 in Chagas Cardiomyopathy
por: Pinto, Bruna F., et al.
Publicado: (2022)

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation
por: Kennedy, Alan, et al.
Publicado: (2022)

Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis
por: Marquez Pete, Noelia, et al.
Publicado: (2020)

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1
por: Kleinpeter, Patricia, et al.
Publicado: (2019)

Prognostic analysis and validation of diagnostic marker genes in patients with osteoporosis
por: Wang, Xing, et al.
Publicado: (2022)

Prognostic significances of PD-L1- and CTLA-4-positive T cells and positive correlations of immunosuppressive marker expression between cancer tissue and peripheral blood in patients with gastric cancer
por: Lee, Kun Hee, et al.
Publicado: (2023)

Clinical Courses of IKAROS and CTLA4 Deficiencies: A Systematic Literature Review and Retrospective Longitudinal Study
por: Hoshino, Akihiro, et al.
Publicado: (2022)

The utility of urinary CD80 as a diagnostic marker in patients with renal diseases
por: Minamikawa, Shogo, et al.
Publicado: (2018)

Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4
Publicado: (1995)

CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4
por: Halliday, Neil, et al.
Publicado: (2020)

A Model for Apoptotic-Cell-Mediated Adaptive Immune Evasion via CD80–CTLA-4 Signaling
por: Yakoub, Abraam M., et al.
Publicado: (2019)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021)

Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients
por: Del Bianco, Paola, et al.
Publicado: (2022)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

Increased Ratio of CD14(++)CD80(+) Cells/CD14(++)CD163(+) Cells in the Infrapatellar Fat Pad of End-Stage Arthropathy Patients
por: Ma, Shuhe, et al.
Publicado: (2021)

Clonality of CD4(+) Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
por: Arakawa, Akiko, et al.
Publicado: (2019)

CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics
por: van der Merwe, P. Anton, et al.
Publicado: (1997)

The Association Between CTLA-4, CD80/86, and CD28 Gene Polymorphisms and Rheumatoid Arthritis: An Original Study and Meta-Analysis
por: Liu, Weixi, et al.
Publicado: (2021)

Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4
por: Fisher, Katie, et al.
Publicado: (2023)

Immune profiling identifies CD8(+) T-cell subset signatures as prognostic markers for recurrence in papillary thyroid cancer
por: Chen, Zhen, et al.
Publicado: (2022)

CTLA-4-Ig internalizes CD80 in fibroblast-like synoviocytes from chronic inflammatory arthritis mouse model
por: Miura, Yoko, et al.
Publicado: (2022)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
por: Williams, Cayman, et al.
Publicado: (2022)

Current understanding of CTLA-4: from mechanism to autoimmune diseases
por: Hossen, Md Munnaf, et al.
Publicado: (2023)

Alternative Immunomodulatory Strategies for Xenotransplantation: CD80/CD86-CTLA4 Pathway-Modified Immature Dendritic Cells Promote Xenograft Survival
por: Tian, Min, et al.
Publicado: (2013)

CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis
por: Soskic, Blagoje, et al.
Publicado: (2021)

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
por: Zhang, Ying, et al.
Publicado: (2022)

CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients
por: Vaddi, Prasanna Kumar, et al.
Publicado: (2023)

Dominant Role of CD80–CD86 Over CD40 and ICOSL in the Massive Polyclonal B Cell Activation Mediated by LAT(Y136F) CD4(+) T Cells
por: Chevrier, Stéphane, et al.
Publicado: (2012)

Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
por: Schneider, Helga, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m04jhbr3sv8fpepfj0mb35judq